- Drugs
- Wednesday, 06 May 2020
India will ship nearly 1,000 tonnes of paracetamol raw material to Europe
The Indian government in March put a hold on exports of several drugs including paracetamol to secure supplies for its people after the coronavirus outbreak disrupted the industry’s supply chain globally. COVID-19 is the respiratory disease caused by the novel coronavirus.
Europe has sought up to 800 tonnes of paracetamol APIs every month, said Dinesh Dua, chairman of the Pharmaceuticals Export Promotion Council of India (Pharmexcil).
“We have been under immense pressure from the European Union for the last 10 days,” Dua said.
The European Union delegation in India did not immediately reply to an email from Reuters requesting comment on the planned shipment.
Indian authorities have asked drugmakers to ensure the country is adequately stocked for up to four months of domestic requirements, Dua said.
India, the world’s main supplier of generic drugs, has shipped 1.9 million tablets and other forms of paracetamol to 31 countries, the foreign ministry said late last month, adding that consignments of anti-malaria drug hydroxychloroquine and paracetamol were being sent to 87 countries on a commercial basis.
Europe is India’s biggest buyer of paracetamol APIs and imports around 12,000 tonnes annually, according to Pharmexcil estimates. The common pain reliever is also sold as acetaminophen.
The novel coronavirus outbreak has killed more than a quarter of a million people and Europe has accounted for 57% of the global death toll.
India has so far reported more than 49,000 cases of COVID-19. The outbreak has not shown any signs of slowing despite a severe lockdown that has confined its population of 1.3 billion to their homes since late March.
Related Industry Updates
MindMed Building Diverse Pipeline and Leadership Position in Psychedelic Inspired Medicines Industry
Jun 27, 2020
US Pharmacy Management System Market is expected to reach US$ 53,139.59 million by 2030
Sep 21, 2023
Allergan Foundation Giving Reaches $95 Million Since Inception
Dec 19, 2019
CMAB Biopharma and Fapon Biopharma Sign Agreement to Develop and Manufacture a Biologic Oncology Asset
Dec 02, 2019
FDA Approves BYSANTI™ (milsaperidone) for Bipolar I and Schizophrenia
Feb 23, 2026
Zongertinib Gets Accelerated FDA Nod for HER2 NSCLC
Aug 14, 2025
DisposeRx Adds New Community Outreach Partners to Stop Prescription Drug Abuse
Jun 10, 2020